Cytheris completes second financing
Cytheris, a privately-held, Paris, France-based biopharmaceutical company focused on immuno-modulation, says it has raised 24.3 million euros ($30.7 million) through a series B financing. The new round will be used to extend Cytheris' current interleukin-7 clinical studies in France and the USA, to move this drug forward into Phase II trials and to complete the preclinical development of its new drug candidate selected from a NKT/Dendritic cell activators platform.
The firm noted that it has attracted two new investors: CDC Entreprises Innovation, a subsidiary of CDC Entreprises (France), which led the round, and ABN AMRO Capital Life Sciences (Netherlands). Existing investors AXA Private Equity (France), Bioam (France), Credit Agricole Private Equity (France), T2C2/Bio 2000 (Canada) and Caisse de Depot et Placement du Quebec (Canada) also participated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze